STOCK TITAN

Director Hussain Abbas gets 8,371 RSUs at Moderna (MRNA)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Moderna, Inc. director Hussain Abbas received a grant of 8,371 restricted stock units on May 6, 2026 as equity compensation. These restricted stock units convert into common stock on a one-for-one basis. The award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to his continued service.

Positive

  • None.

Negative

  • None.
Insider Hussain Abbas
Role null
Type Security Shares Price Value
Grant/Award Restricted Stock Units 8,371 $0.00 --
Holdings After Transaction: Restricted Stock Units — 8,371 shares (Direct, null)
Footnotes (1)
  1. Restricted stock units convert into common stock on a one-for-one basis. The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service.
RSUs granted 8,371 units Restricted stock unit award to director on May 6, 2026
Exercise/conversion price $0.00 per share Restricted stock units convert to common stock at no cash cost
Post-grant RSU holdings 8,371 units Total restricted stock units held following the reported transaction
Restricted Stock Units financial
"Restricted stock units convert into common stock on a one-for-one basis."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
vest in full financial
"The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders"
Annual Meeting of Shareholders financial
"will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders"
A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hussain Abbas

(Last)(First)(Middle)
C/O MODERNA, INC.
325 BINNEY STREET

(Street)
CAMBRIDGE MASSACHUSETTS 02142

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Moderna, Inc. [ MRNA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/06/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(1)05/06/2026A8,371 (2) (2)Common Stock8,371$08,371D
Explanation of Responses:
1. Restricted stock units convert into common stock on a one-for-one basis.
2. The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service.
/s/ James Dillon, As Attorney-in-Fact05/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Moderna (MRNA) disclose for director Hussain Abbas?

Moderna disclosed that director Hussain Abbas received 8,371 restricted stock units as an equity grant. These units represent a compensation award rather than an open-market purchase or sale, and will convert into common stock on a one-for-one basis after vesting.

How many restricted stock units did Hussain Abbas receive from Moderna (MRNA)?

Hussain Abbas received 8,371 restricted stock units from Moderna. This entire grant is currently unvested and is intended to convert into an equal number of common shares, providing stock-based compensation aligned with Moderna’s equity program for its directors.

When do Hussain Abbas’s Moderna (MRNA) restricted stock units vest?

The restricted stock units granted to Hussain Abbas vest in full on the earlier of May 6, 2027, or Moderna’s next Annual Meeting of Shareholders. Vesting is contingent on his continued service with the company through that vesting date trigger.

What does one-for-one conversion mean for Moderna (MRNA) restricted stock units?

One-for-one conversion means each restricted stock unit granted to Hussain Abbas will turn into one share of Moderna common stock upon vesting. For his 8,371-unit award, full vesting would result in 8,371 common shares being issued to him.

Is Hussain Abbas’s Moderna (MRNA) Form 4 transaction a stock purchase or sale?

The Form 4 transaction is not an open-market purchase or sale. It is a grant classified as a grant, award, or other acquisition of 8,371 restricted stock units, provided as stock-based compensation rather than a voluntary market trade by the director.